An effective pharmacological hydrogel induces optic nerve repair and improves visual function

Area of Science:

• Ophthalmology
• Neuroscience
• Regenerative Medicine

Background:

• Irreversible eye conditions like glaucoma and optic neuropathy cause blindness due to the optic nerve's inability to regenerate.
• Current treatments for optic nerve damage are ineffective, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

• To investigate the potential of a combination therapy using small molecules 3BDO and trichostatin A (TSA) for inducing optic nerve regeneration.
• To evaluate the efficacy of sustained release of 3BDO and TSA via thermosensitive hydrogel for treating optic nerve injury and glaucoma models.

Main Methods:

• Small molecules 3BDO (mTOR regulator) and TSA (HDAC regulator) were combined and encapsulated in a thermosensitive hydrogel for sustained intravitreal release over 4 weeks.
• The hydrogel formulation was administered to a mouse model of optic nerve crush injury to assess regeneration.
• The treatment's effects on axon protection and visual function were evaluated in an aged mouse model of glaucoma.

Main Results:

• The sustained release of 3BDO and TSA effectively induced optic nerve regeneration in mice with optic nerve crush injury.
• The combination therapy demonstrated neuroprotective effects on axon projections in aged glaucoma model mice.
• Improved visual responses were observed in aged mice treated with the 3BDO and TSA hydrogel formulation.

Conclusions:

• Local, sustained delivery of 3BDO and TSA via hydrogel offers a promising new strategy for optic nerve repair.
• This small molecule-based approach provides a foundation for developing pharmacological treatments for irreversible blinding eye diseases.
• The findings suggest a potential therapeutic avenue for conditions such as glaucoma and traumatic optic neuropathy.